Toni-Uebari Thelma K, Rees John
General Adult Psychiatry, Parklands Hospital, Basingstoke, Hampshire, UK.
BMJ Case Rep. 2013 Jan 22;2013:bcr2012007172. doi: 10.1136/bcr-2012-007172.
A case is presented of a 23-year-old lady with treatment-resistant schizoaffective disorder who had responded well to treatment with clozapine. Fifteen months after satisfactory use of clozapine she had 'red alerts' from routine haematological monitoring indicating neutropenia. Clozapine was discontinued and she was admitted to the psychiatric hospital to manage the aftermath of discontinuing clozapine and start alternative treatment with other antipsychotics. Her mental health rapidly deteriorated. Adequate trials with amisulpride, haloperidol, olanzapine and flupenthixol decanoate yielded little improvement in her clinical state. After 9 months of non-response to other antipsychotic medications, she was rechallenged with clozapine, followed by improvement in her mental state. She was eventually discharged home after 14 months of hospitalisation in a stable mental state. She remained mentally stable in the community on clozapine for 18 months after rechallenge, with no further red alerts.
本文介绍了一名23岁患有难治性分裂情感障碍的女性病例,她对氯氮平治疗反应良好。在氯氮平使用情况良好的15个月后,常规血液学监测发出“红色警报”,提示出现中性粒细胞减少。停用氯氮平后,她入住精神病院,以处理停用氯氮平的后果,并开始使用其他抗精神病药物进行替代治疗。她的心理健康状况迅速恶化。使用氨磺必利、氟哌啶醇、奥氮平和癸酸氟奋乃静进行的充分试验,对她的临床状况改善甚微。在对其他抗精神病药物无反应9个月后,她再次接受氯氮平治疗,随后精神状态有所改善。在住院14个月后,她最终以稳定的精神状态出院回家。再次接受氯氮平治疗后,她在社区中保持了18个月的精神稳定,没有再出现红色警报。